Trans Asia Peer Comparison

BSE: 530783

₹3.20

₹-0.16 (-4.76%)

As on 19-Oct-2021IST

Market cap

₹2 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

4

Div. Yield

0 %

Edit

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	2	31,863	30,485	28,611	27,284
Revenue (₹ Cr)	--	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-5.59	414.00	288.22	-371.81	387.35
Net Margin (%)	-46,583.33	11.23	14.79	-3.93	26.01
RoE (%)	-4.30	8.38	29.77	-3.85	25.18
Price to Earnings	--	77.90	105.77	--	70.64
Price-To-Book	3.98	6.33	22.71	3.57	15.78

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	0.00	2,843.99	263.02	--	239.64
Total Income	0.00	2,904.07	281.09	--	242.49
Total Expenditure	0.08	2,746.23	182.42	--	198.63
EBITDA	-0.08	97.76	80.60	--	41.02
Depreciation	--	224.14	18.45	--	3.52
EBIT	-0.08	-126.38	62.15	--	37.50
Interest	0.00	275.74	6.20	--	5.59
Other Income	--	60.08	18.07	--	2.84
Exceptional Items	-1.17	--	--	--	--
Profit before Tax	-0.08	-342.04	74.01	--	34.75
Provision for Tax	0.08	-204.09	24.60	--	7.28
Profit after Tax	-0.08	-137.95	49.41	--	27.47

Liabilities (₹ Cr)

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	6.01	2,671.67	340.50	--	111.81
Minority Interest	--	385.79	--	--	--
Non-Current Liabilities	0.01	1,194.85	9.30	--	25.46
Current Liabilities	0.74	3,497.18	77.54	--	94.61
Total Liabilities	6.76	8,147.66	430.39	--	231.89

Assets (₹ Cr)

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	4.90	5,319.66	162.50	--	104.93
Current Assets	1.86	2,400.54	264.84	--	121.04
Total Assets	6.76	8,147.66	430.39	--	231.89
Total Debt*	0.15	3,213.23	30.27	--	59.42
Net Current Assets	1.12	-1,096.64	187.31	--	26.42
Contingent Liabilities	--	641.08	46.45	--	0.07

Cashflow (₹ Cr)

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	0.66	648.96	5.47	--	27.08
Cash Flow from Investing Activities	-0.66	-155.53	-84.34	--	-23.94
Cash from Financing Activities	--	-679.58	80.07	--	0.19
Net Cash Inflow / Outflow	0.00	-186.15	1.21	--	3.33

Ratios

Profitability Ratios

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-1.33	-1.11	26.00	--	27.09
ROE (%)	-1.36	-5.22	18.67	--	29.78
ROA (%)	-1.22	-1.80	13.65	--	12.34
EBIT Margin (%)	--	5.55	37.51	--	18.30
Net Margin (%)	--	-4.75	17.58	--	11.33
Cash Profit Margin (%)	--	3.03	25.80	--	12.93

Growth Ratios

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	--	-20.24	71.02	--	0.47
EBIT Growth (%)	-23.86	1,004.01	159.60	--	3.29
Net Profit Growth (%)	93.73	55.76	168.16	--	17.92
EPS Growth (%)	93.73	64.44	148.52	--	17.92
Book Value Growth (%)	-1.35	-0.03	68.83	--	34.77

Valuation Ratios

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	0.00	0.00	--	0.00
Price / Book Value	0.30	0.72	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	-23.67	30.78	0.00	--	1.51
Market Cap (₹ Cr)	--	1,913.03	0.00	--	0.00

Solvency Ratios

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.03	1.22	0.09	--	0.56
Short term debt to equity ratio	0.02	0.34	0.06	--	0.30
Current Ratio	2.51	0.69	3.42	--	1.28
Quick Ratio	2.51	0.48	2.93	--	0.73
Interest Coverage	-67.10	-0.24	12.93	--	7.22

Operating Efficiency Ratios

	Trans Asia	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	--	43.70	53.26	--	23.54
Asset Turnover	0.00	0.37	0.73	--	1.08
Receivable days	--	161.49	155.79	--	100.90
Inventory Days	--	98.54	39.61	--	69.31
Payable days	--	263.19	159.03	--	169.65
Cash Conversion Cycle	--	-3.16	36.37	--	0.56

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.